Threshold Pharmaceuticals (United States)
- Research works
- 80 ▼ 90% vs 2013–17
- Citations
- 1.6k 20.3 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 23% world 28%
Not ranked overall: Threshold Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Threshold Pharmaceuticals (United States) specialise in?
Where its research is concentrated relative to its size: Biochemistry, Genetics and Molecular Biology takes 6.7× the share of its output that it takes of world research.
- Biochemistry, Genetics and Molecular BiologyField · 36.9 works6.7×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Who are the top researchers at Threshold Pharmaceuticals (United States)?
Ranked on the composite score, Jessica D. Sun, Charles P. Hart and Fanying Meng lead among researchers whose main affiliation is Threshold Pharmaceuticals (United States).
- 1 Jessica D. Sun United States · #759,867 worldwide 63 citations · 21 works
- 2 Charles P. Hart United States · #1,290,912 worldwide 36 citations · 36 works
- 3 Fanying Meng United States · #1,560,858 worldwide 9 citations · 20 works
Which keywords describe research at Threshold Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Tumor Microenvironment, HIF-1, Warburg Effect, Immunotherapy, Tumor Targeting, Chemotherapy, Reactive Oxygen Species and Cancer Therapy.
- m6A-seq
- R&D Subsidies
- Hematopoietic Stem Cells
- Topoisomerases
- DNA
- Minimal Residual Disease
- Heterocyclic Compounds
- Mitochondrial Dysfunction
- Cancer Genomics
- p53
- Cell Cycle
- Tumor Suppression
- Photothermal Therapy
- Prognostic Factors
- Arginine Deprivation
- Gene Therapy
- Cancer Therapy
- Chemotherapy
- Immunotherapy
- HIF-1
- Tumor Microenvironment
- Warburg Effect
- Tumor Targeting
- Reactive Oxygen Species
- Nanoparticles
- Targeted Therapy
- Bacterial Therapy
- Fluorescence Imaging
- Apoptosis
- Genomic Instability
- Clinical Trials
- Medicinal Chemistry
- Mutational Signatures
- Metastasis
- Genetic Variants
- Staging System
- Proteasome Inhibitors
- Genomic Profiles
- Private R&D
- Small-Cell Lung Cancer
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Tumor Microenvironment17▲ 59×3 topics
- HIF-116▲ 268×1 topic
- Warburg Effect16▲ 268×1 topic
- Immunotherapy14▲ 26×8 topics
- Tumor Targeting9▲ 84×3 topics
- Chemotherapy6▲ 10×9 topics
- Reactive Oxygen Species5▲ 13×4 topics
- Cancer Therapy5▲ 10×7 topics
- Nanoparticles5▲ 4.6×3 topics
- Gene Therapy5▲ 23×2 topics
- Targeted Therapy5▲ 28×4 topics
- Arginine Deprivation4▲ 127×1 topic
- Bacterial Therapy4▲ 127×1 topic
- Prognostic Factors4▲ 12×6 topics
- Fluorescence Imaging4▲ 46×1 topic
- Photothermal Therapy4▲ 61×1 topic
- Apoptosis3▲ 11×5 topics
- Tumor Suppression3▲ 32×2 topics
- Genomic Instability3▲ 28×2 topics
- Cell Cycle3▲ 55×1 topic
- Clinical Trials3▲ 5.2×3 topics
- p533▲ 73×1 topic
- Medicinal Chemistry2▲ 7.7×4 topics
- Cancer Genomics2▲ 48×1 topic
- Mutational Signatures2▲ 48×1 topic
- Mitochondrial Dysfunction2▲ 6.6×3 topics
- Metastasis2▲ 7.1×3 topics
- Heterocyclic Compounds2▲ 14×3 topics
- Genetic Variants2▲ 9.6×3 topics
- Minimal Residual Disease2▲ 31×2 topics
- Staging System2▲ 34×2 topics
- DNA2▲ 61×1 topic
- Proteasome Inhibitors2▲ 29×2 topics
- Topoisomerases2▲ 61×1 topic
- Genomic Profiles2▲ 55×1 topic
- Hematopoietic Stem Cells2▲ 19×2 topics
- Private R&D2▲ 110×1 topic
- R&D Subsidies2▲ 110×1 topic
- Small-Cell Lung Cancer2▲ 55×1 topic
- m6A-seq2▲ 23×1 topic
Which research topics does Threshold Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Child Abuse and Related Trauma, Ophthalmology and Eye Disorders, Cerebral Venous Sinus Thrombosis and Biomedical Text Mining and Ontologies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Child Abuse and Related Trauma Pediatrics, Perinatology and Child Health 0 works
- 2 Ophthalmology and Eye Disorders Pathology and Forensic Medicine 0 works
- 3 Cerebral Venous Sinus Thrombosis Neurology 0 works
- 4 Biomedical Text Mining and Ontologies Molecular Biology 0 works
- 5 Genomics and Rare Diseases Genetics 0 works
- 6 Machine Learning in Bioinformatics Molecular Biology 0 works
- 7 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 0 works
- 8 Cancer, Stress, Anesthesia, and Immune Response Psychiatry and Mental health 0 works
- 9 Estrogen and related hormone effects Genetics 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Threshold Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 90% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in San Francisco
- University of California, San Francisco
- San Francisco State University
- University of San Francisco
- San Francisco VA Medical Center
- University of California San Francisco Medical Center
- San Francisco General Hospital
- Institute on Aging
- California Pacific Medical Center
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.